Stephens Reiterates “Equal Weight” Rating for Lifecore Biomedical (NASDAQ:LFCR)

Lifecore Biomedical (NASDAQ:LFCR)‘s stock had its “equal weight” rating reissued by equities research analysts at Stephens in a research note issued on Friday,Benzinga reports. They presently have a $6.00 price target on the stock. Stephens’ target price points to a potential downside of 21.26% from the stock’s current price.

Separately, Craig Hallum boosted their price objective on Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, November 22nd.

Lifecore Biomedical Price Performance

Lifecore Biomedical stock opened at $7.62 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.83 and a debt-to-equity ratio of 12.90. Lifecore Biomedical has a 52-week low of $3.68 and a 52-week high of $8.90. The firm has a market cap of $280.62 million, a PE ratio of 95.25 and a beta of 0.98. The company’s 50 day moving average is $7.03 and its two-hundred day moving average is $5.80.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings data on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a negative return on equity of 382.65% and a net margin of 5.09%. On average, research analysts expect that Lifecore Biomedical will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Lifecore Biomedical

Large investors have recently bought and sold shares of the business. Renaissance Technologies LLC acquired a new position in shares of Lifecore Biomedical during the 2nd quarter worth about $56,000. Creative Planning purchased a new stake in Lifecore Biomedical during the third quarter worth approximately $69,000. Public Employees Retirement System of Ohio acquired a new position in Lifecore Biomedical in the third quarter valued at approximately $119,000. Rhumbline Advisers increased its stake in Lifecore Biomedical by 1,668.5% in the second quarter. Rhumbline Advisers now owns 26,899 shares of the company’s stock valued at $138,000 after purchasing an additional 25,378 shares during the last quarter. Finally, Barclays PLC raised its holdings in Lifecore Biomedical by 301.7% during the third quarter. Barclays PLC now owns 29,944 shares of the company’s stock worth $147,000 after purchasing an additional 22,489 shares in the last quarter. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.